Prof Ashok Venkitaraman elected as Fellow of prestigious AACR Academy
Professor Ashok Venkitaraman, who is Director of the Cancer Science Institute of Singapore (CSI Singapore), Distinguished Professor of Medicine at NUS Yong Loo Lin School of Medicine, and Research Director at the Agency for Science, Technology & Research’s (A*STAR) Institute of Molecular and Cell Biology, has been elected to the 2025 class of Fellows of the prestigious American Association for Cancer Research (AACR) Academy. Standings among an exceptional group of 33 newly inducted Fellows this year, he is honoured for his pioneering contributions to cancer research.
Prof Venkitaraman’s research has elucidated the tumour suppressive functions of the hereditary breast cancer gene, BRCA2, in genome maintenance. His work has been instrumental in uncovering the mechanisms responsible for carcinogenesis in BRCA2 mutation carriers, and advancing technologies to accelerate drug discovery, thereby establishing a foundation for the development of novel cancer therapies.
“I am deeply honoured to be elected to the AACR Academy, the world’s oldest and largest cancer research organisation. It is a great privilege to join such a distinguished group of global colleagues who have made transformative contributions for the lasting benefit of patients,” said Prof Venkitaraman.
He added, “This recognition is not mine alone—it also felicitates the achievements of a far-flung family of staff, students, fellows, and collaborators in my team whose contributions and camaraderie have made my work possible. It also underscores the excellence of research conducted at CSI Singapore, made possible through the generous support of our funders and donors. I am proud to be part of the remarkable scientific community at NUS and A*STAR in Singapore, and remain committed to advancing discoveries that improve patient outcomes worldwide.”
The AACR Academy honours outstanding scientists who have made significant contributions in driving innovation and progress in the fight against cancer. Fellows of the AACR Academy serve as a global brain trust of leading experts in cancer science and medicine, working to advance the AACR’s mission to prevent and cure all cancers through research, education, collaboration, communication, advocacy, and funding for cancer research.
Fellows of the AACR Academy are nominated and elected through a meticulous peer-reviewed process that rigorously evaluates each candidate’s scientific achievements and contributions to the global cancer research community. Scientists whose work have made a deep and lasting impact on cancer research and related fields are considered for election and induction into the AACR Academy.
“The 2025 class of Fellows of the AACR Academy perfectly exemplifies the pinnacle of scientific innovation and excellence, with their collective scientific contributions fundamentally advancing our understanding of cancer biology and treatment. We are thrilled to welcome them to our distinguished group of Fellows of the AACR Academy, now numbering 375, and look forward to celebrating their groundbreaking achievements at our upcoming Annual Meeting in April 2025,” said AACR Chief Executive Officer Dr Margaret Foti.
